On October 23, 2023, the underwriters of Know Labs, Inc.'s (the "Company") previously announced offering of its common stock, par value $0.001 per share ("Common Stock") (the "Offering"), partially exercised their over-allotment option under the Underwriting Agreement by and between the Company and the underwriters dated September 26, 2023, electing to purchase an additional 883,061 shares of Common Stock at a purchase price to the public of $0.25 per share. The partial exercise of the over-allotment option closed on October 26, 2023. After giving effect to the partial exercise of the over-allotment option, the total number of shares of common stock sold by the Company in the Offering increased to 28,883,061 shares. The Company also issued additional warrants to the Representatives (as defined in the Underwriting Agreement) to purchase an aggregate of 61,814 shares of Common Stock at an exercise price of $0.25 per share, subject to adjustments, with the same terms as the warrants issued in connection with the initial closing of the Offering.
Know Labs Inc. published this content on 30 October 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 30 October 2023 10:08:26 UTC.
Know Labs, Inc. is a provider of non-invasive blood glucose monitoring solutions. The Company is focused on the development and commercialization of its proprietary sensor technology utilizing radio and microwave spectroscopy. When paired with its machine learning platform, the Companyâs Bio-RFID sensor technology platform identifies and measures various material or analyte using electromagnetic energy to detect, record, identify and measure the signature of said materials or analytes. The data obtained with its sensor technology is analyzed with the Companyâs trade secret algorithms. The Company is focused on analytes relating to human health, the identification, of which provide diagnostic information and require, by their nature, clearance by the United States Food and Drug Administration. The first among those analytes is the non-invasive monitoring of blood glucose levels. Its device provides the user with real-time information on their blood glucose levels.
KNOW LABS, INC. 
